Abstract
Aim:
To assess the effect of tiotropium 18mcg once daily on chronic obstructive pulmonary disease (COPD) exacerbations and exacerbation-related hospitalisations using a patient-level pooled analysis.
Methods:
All completed randomised, placebo-controlled, parallel-group tiotropium trials with a duration of ≥24 weeks were included (n=9). An exacerbation was defined in each study as ≥2 respiratory symptoms lasting ≥3 days, and requiring treatment with antibiotics and/or systemic steroids and/or hospitalisation.
Results:
Compared with placebo (2,862 patients), tiotropium (3,309 patients) significantly reduced by 21% both the risk of COPD exacerbation (95% confidence interval [CI] 0.73–0.86; p<0.0001) and the risk of exacerbation-associated hospitalisation (95% CI 0.65–0.96; p=0.015). Time to first exacerbation and first associated hospitalisation were increased. The protective effect of tiotropium was consistent regardless of age, gender, inhaled corticosteroid use and disease severity.
Conclusion:
This analysis provides further confirmatory evidence that tiotropium reduces the risk of exacerbation and associated hospitalisation.
Similar content being viewed by others
Article PDF
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
Dr D Halpin has received reimbursement for attending a symposium and a fee for speaking from Boehringer Ingelheim GmbH and Pfizer Inc. Drs S Menjoge and K Viel are both employees of Boehringer Ingelheim GmbH, the manufacturer of tiotropium (Spiriva*).
Rights and permissions
About this article
Cite this article
Halpin, D., Menjoge, S. & Viel, K. Patient-level pooled analysis of the effect of tiotropium on COPD exacerbations and related hospitalisations. Prim Care Respir J 18, 106–113 (2009). https://doi.org/10.4104/pcrj.2009.00017
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.4104/pcrj.2009.00017